Jutta Horejs-Hoeck
Funding-Akquise kumuliert: ca. € 2 900 000
| Dauer der Förderung | Fördergeber, Förderungs-ID und Projekttitel |
|---|---|
| Aktuell geförderte Projekte | |
| 2021-2025 | The NLRP3/eiF2 axis in AML Austrian Science Fund Grant ID: P33969 |
| 2021-2023 | Effects of NPepZn on the immune system EVER Neuropharma |
| 2021-2023 | CCS II-IOS: The microenvironment in acute myeloid leukemia Cancer Cluster/Bundesland Salzburg |
| 2020-2024 | Directing the immune response through designed nanomaterials (DIRNANO) EU Horizon 2020 ITN Grant ID: 956544 |
| 2019-2022 | Epigenetics of Immunity in Cancer (EPIC) EU Horizon 2020 Interreg V-A Italia-Austria (co-applicant, PI) |
| 2019-2022 | Quantitative detection of bacgerial endotoxin by novel nanotechnological approaches (ENDONANO) EU Horizon 2020 Grant ID: 812661 |
| 2018-2022 | NLRs in type 2 inflammation Austrian Science Fund Grant ID: W1213 |
| — | — |
| Bisher geförderte Projekte | |
| 2017-2020 | Canster Cluster Salzburg Tumor-microenvironment in AML |
| 2017-2020 | Austrian Science Fund Grant ID: P29941 NOD1 controls tolerogenic DCs |
| 2016-2020 | EVER Neuropharma Anti-inflammatory effects of Cerebrolysin |
| 2014-2018 | Austria Science Fund Grant ID: 25696 Signaling crosstalk between NOD2 and IL-31 |
| 2015-2016 | AAI Careers in Immunology Fellowship Grant ID: AI0615_P NOD1 counteracts anti-inflammatory effects mediated by IL-10 |
| 2011-2015 | Austrian Science FundGrant ID: P23933 IL-31 regulates DC-mediated T cell responses in the course of atopic dermatitis |
| 2009-2013 | Austrian Science Fund Grant ID: P23933 The role of IL-31/IL-31R interactions in dendritic cells for the activation of human T cells |
Projektbeteiligungen
See also:
Jutta Horejs-Hoeck
